^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | vilastobart (XTX101) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Published date:
11/30/2023
Excerpt:
XTX101-01/02-001 (NCT04896697) Part 1A examined XTX101 in 3+3 dose escalation in patients (pts) with advanced solid tumors. Part 1B examined pharmacodynamic (PD) biomarkers...One pt, at 150 mg Q6W, with PD-L1 negative non-small cell lung cancer had a confirmed partial response (PR) ongoing at 36 weeks...XTX101...showed evidence of monotherapy clinical activity with a confirmed PR.
Trial ID:
